“Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK (MAPK) pathway”, unpublished, filed January 20, 2022

 

"Combinations for the treatment of cancer using quiescent cell targeting and inhibitors of mitosis"

 

“Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors” 

 

"A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects"

 

"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3"

 

Abstract Number: 5161

Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinics

 

Patent "Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases"; WO 2018119039

 

Abstract Number: 14670

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.

 

Abstract Number: 3038

Implications of DYRK1B kinase in ovarian cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for ovarian cancers

​

 

How to design potent and selective DYRK1B inhibitors? Molecular modeling study.

 

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL.

​

DYRK1B inhibitors prevent pharmacologic quiescence and sensitize lung cancers to EGFR inhibitors.

Oral presentation

Date and Time:  January 13th 2016 8AM

Location: The Parc 55 San Francisco Track A